Edition:
United Kingdom

Mersana Therapeutics Inc (MRSN.OQ)

MRSN.OQ on NASDAQ Stock Exchange Global Select Market

4.78USD
14 Dec 2018
Change (% chg)

$-0.22 (-4.40%)
Prev Close
$5.00
Open
$4.91
Day's High
$4.99
Day's Low
$4.75
Volume
12,599
Avg. Vol
34,972
52-wk High
$23.67
52-wk Low
$4.75

Summary

Name Age Since Current Position

David Mott

52 2017 Independent Chairman of the Board

Anna Protopapas

53 2016 President, Chief Executive Officer, Director

David Spellman

41 2018 Chief Financial Officer

Michael Kaufman

60 2016 Senior Vice President - Chemistry, Manufacturing and Controls

Timothy Lowinger

54 Chief Scientific Officer

Wayne Foster

Vice President - Finance

Dirk Huebner

2018 Chief Medical Officer

Eva Jack

50 2013 Chief Business Officer

Lawrence Alleva

68 2017 Independent Director

Willard Dere

64 2018 Independent Director

Andrew Hack

44 2017 Independent Director

Kristen Hege

54 2016 Independent Director

Biographies

Name Description

David Mott

Mr. David M. Mott is an Independent Chairman of the Board of the Company. Mr. Mott is the Chairman of the Board at Mersana Therapeutics Inc. He is a General Partner at New Enterprise Associates, where he leads the healthcare investing practice. Before joining NEA, he spent 16 years at MedImmune in roles of increasing responsibility, including Chief Operating Officer, Chief Financial Officer and CEO, building the company from a venture-backed startup into one of the top five biotechnology companies in the world, He led the sale of MedImmune to AstraZeneca in 2007 for $15.6 billion, and at the time of his departure in 2008, MedImmune had annual revenues in excess of $1.5 billion, annual R&D in excess of $650 million and approximately 3,000 employees. Mr. Mott is also Chairman of 3-V Biosciences, Cydan, Prosensa, TESARO and Zyngenia and a director of Ardelyx, Edimer Pharmaceuticals and Epizyme. He received his B.A. from Dartmouth College.

Anna Protopapas

Ms. Anna Protopapas is the President, Chief Executive Officer, Director of the Company. She bringing a substantial track record of executive leadership and business experience in the biotech industry. Prior to Mersana, Ms. Protopapas was President of Millennium, where she led Takeda Pharmaceutical Co.’s $1.3 billion oncology business. Ms. Protopapas also served as the Executive Vice President of Global Business Development for Takeda Pharmaceuticals where she was responsible for global acquisitions, partnering, licensing and venture investing. In this role, she led Takeda’s $12 billion acquisition of Nycomed, a critical step in the company’s globalization. Ms. Protopapas was a member of Takeda’s executive committee and was elected a corporate officer in 2011. Earlier, Ms. Protopapas was an executive officer at Millennium Pharmaceuticals and served in various senior leadership positions, playing an integral role in the company’s transformation from a genomics start-up to a fully integrated oncology leader. She was instrumental in the sale of Millennium to Takeda for $8.8 billion. Ms. Protopapas earned her bachelor’s degree in science and engineering from Princeton University, a master’s in chemical engineering practice from the Massachusetts Institute of Technology and an M.B.A. from Stanford Graduate School of Business.

David Spellman

Mr. David A. Spellman is the Chief Financial Officer of the Company. He joins the Company from Vertex Pharmaceuticals Incorporated (“Vertex”), where he worked for 12 years, most recently as Vice President of Corporate, Commercial and International Finance, responsible for global financial planning across the company.

Michael Kaufman

Dr. Michael Kaufman, Ph.D., is the Senior Vice President - Chemistry, Manufacturing and Controls since February 2016. Previously, from 2012 to 2016, Dr. Kaufman served as Vice President, Technical Development at Biogen, Inc. Before Biogen, Dr. Kaufman spent 10 years at Millennium Pharmaceuticals, most recently as Vice President, Pharmaceutical Sciences. Before that, he spent 15 years at Merck and Co., Inc. serving in various roles. Dr. Kaufman received a B.S. in Chemistry from the State University of New York, Stony Brook and a Ph.D. in Physical Organic Chemistry from the University of California, Berkeley.

Timothy Lowinger

Dr. Timothy B. Lowinger, Ph.D., is the Chief Scientific Officer of Mersana Therapeutics, Inc. Dr. Lowinger bringing nearly 15 years of global scientific leadership and drug discovery experience in the pharmaceutical and biotech industries. Over the course of his career at Bayer Pharmaceuticals in the US, Japan and Germany, he contributed to the discovery of more than 15 preclinical and clinical drug candidates in the areas of oncology, asthma, inflammation, virology, obesity and diabetes. Most notably, Dr. Lowinger is a co-inventor of the pioneering anti-angiogenic agent Nexavar (sorafenib), approved for the treatment of renal and hepatocellular cancer, as well as Stivarga (regorafenib), approved for the treatment of metastatic colorectal cancer. Dr. Lowinger has published more than 40 scientific papers and is a co-inventor on more than 40 patents. He has a B.Sc. (Hons.) in Chemistry and a Ph.D. in Organic Chemistry from the University of British Columbia and was a Merck Postdoctoral Fellow at the Ohio State University in the lab of Professor Leo A. Paquette. He currently serves on the Scientific Advisory Board of Keystone Symposia.

Wayne Foster

Mr. Wayne Foster, CPA, is the Vice President - Finance at Mersana Therapeutics Inc. Mr. Foster has held management positions in several life science and technology companies. Prior to joining Mersana in 2013, he served for nine years as Senior Director of Finance at Tolerx, Inc. Mr. Foster also served as Senior Manager at Arthur Andersen LLP where he specialized in emerging life science and technology companies. He earned his B.B.A. in Accounting from the University of Massachusetts Amherst.

Dirk Huebner

Mr. Dirk Huebner is Chief Medical Officer of the company. Prior to joining Mersana, Dr. Huebner served as Vice President, Head of Development, for Boston Biomedical, where he built a robust clinical development team and oversaw the clinical development of several early stage compounds. Prior to that, he spent six years at Takeda Oncology as Executive Medical Director. During Dr. Huebner's tenure at Takeda Oncology, he served as the global clinical lead for ADCETRIS® (brentuximab vedotin), an ADC that treats select types of lymphoma. In that role, he led the regulatory approval of ADCETRIS in Europe and the design and implementation of the subsequent registration-enabling studies for the compound. Prior to Takeda, he held roles of increasing leadership in global oncology drug development at Genzyme, Roche, and Bristol-Myers Squibb. Dr. Huebner received his Medical Doctor degree from the Free University in Berlin, Germany and completed a medical residency in the Department of Urology, University Hospital Eppendorf, Hamburg.

Eva Jack

Ms. Eva M. Jack is the Chief Business Officer of the Company, since November 2013. Previously, from 2012 to 2013, she served as a consultant to various biotech companies and investors on business and financing strategies. Before that, she served as Chief Business Officer of Pulmatrix from 2010 to 2012. Before Pulmatrix, she spent six years at MedImmune, the worldwide biologics unit of AstraZeneca, as Managing Director of MedImmune Ventures, overseeing investments in private biotechnology companies, and as a Director in MedImmune's Business Development group. Earlier in her career, Ms. Jack held a variety of positions at Intel Corp. Ms. Jack received a B.A. from the University of Virginia and a master's in health sciences from The Johns Hopkins University.

Lawrence Alleva

Mr. Lawrence M. Alleva is an Independent Director of the company. He is a Certified Public Accountant (inactive) and is a former partner with PwC, where he worked for 39 years until his retirement in June 2010, including 28 years’ service as a partner. He has worked with numerous pharmaceutical and biotechnology companies as clients and served PwC in a variety of office, regional and national practice leadership roles, most recently as the U.S. Ethics and Compliance Leader for the firm’s Assurance Practice from 2006 until 2010. Mr. Alleva currently serves as a director and chair of the audit committee for multiple public companies: Tesaro Inc., Bright Horizons Family Solutions Inc. and Adaptimmune Therapeutics plc. He previously served as a Trustee of Ithaca College for over 20 years. Mr. Alleva graduated from Ithaca College with a B.S. in Accounting. He attended Columbia University Executive MBA (non-degree) Program.

Willard Dere

Dr. Willard H. Dere, M.D., is an Independent Director of the Company. Dr. Dere serves as the Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Associate Dean, Clinical and Translational Science, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical and Translational Science at the University of Utah Health Sciences Center. Dr. Dere previously held important scientific and development leadership positions in the biopharmaceutical industry for 25 years. He joined Amgen in 2003, where he held multiple roles including head of global development and both corporate and international chief medical officer. He began his career at Eli Lilly in 1989 and held a number of different roles in clinical pharmacology, regulatory affairs and both early-stage translational and late-stage clinical research. He earned his undergraduate and medical degrees at the University of California, Davis, completed his internal medicine residency training at the University of Utah, and completed his postdoctoral training in endocrinology and metabolism at the University of California, San Francisco.

Andrew Hack

Dr. Andrew A. F. Hack, M.D., Ph.D., is an Independent Director of the Company. Dr. Hack has served as a member of our Board of Directors since January 2017. Since July 2015, Dr. Hack has served as Chief Financial Officer of Editas Medicine. Previously, from 2011 until 2015, he served as a portfolio manager at Millennium Management, where he ran a healthcare fund focused on biotechnology, pharmaceutical and medical device companies. Before Millennium Management, Dr. Hack was an analyst at HealthCor Management from 2008 to 2011. Prior to HealthCor Management, Dr. Hack served as an analyst at Carlyle-Blue Wave Partners and a principal of the MPM BioEquities Fund. Dr. Hack started his investment career at Banc of America Securities, covering the biotechnology sector. He was also a co-founder of Reify Corporation, a life science tools and drug discovery company. Dr. Hack received a B.A. in Biology, an M.D. and a Ph.D. all from the University of Chicago. We believe that Dr. Hack's financial background, as well as his experience in the biotechnology sector and his medical background, qualify him to serve as a member of our Board of Directors.

Kristen Hege

Dr. Kristen M. Hege, M.D., is an Independent Director of the Company. Dr. Hege has served as a member of our Board of Directors since August 2016. Dr. Hege was hired in 2010 as Vice President, Translational Development, and is currently a Corporate VP Translational Development at Celgene Corporation. She has also held an active faculty position at the University of California, San Francisco Medical Center since 1996, most recently as Clinical Professor of Medicine, Hematology/Oncology, serving in that role as a volunteer since 2008. Prior to Celgene, she served as Chief Medical Officer at Cellerant Therapeutics and Acting Chief Medical Officer at Aragon Pharmaceuticals and Theraclone Sciences. Dr. Hege was also a Vice President, Clinical Research and Development at Cell Genesys. Dr. Hege is a volunteer at-large director for the Society for Immunotherapy of Cancer and observing board member at Arcus Biosciences. Dr. Hege previously served on the boards of directors for BayBio/California Life Sciences Association from 2014 to 2016 and as a volunteer for Flexus Biosciences from 2014 to 2015 as a board observer. Dr. Hege received a B.A. in Biochemistry from Dartmouth College summa cum laude, an M.D. from University of California, San Francisco and Board certification in Hematology and Medical Oncology from the University of California, San Francisco. We believe that Dr. Hege's medical background and experience in the biotechnology industry qualify her to serve as a director.

Basic Compensation